Frontiers | Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
Indications & Dosing | DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) HCP
Recent Advances in the Treatment of Patients with Multiple Myeloma
Oxford Myeloma Group
Multiple Myeloma
JCM | Free Full-Text | Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma
![PDF] Treatment of relapsed and refractory multiple myeloma | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/5b69ac4a309afefbc2e325fbf5b369be3c2eda8f/7-Figure1-1.png "PDF] Treatment of relapsed and refractory multiple myeloma | Semantic Scholar")
PDF] Treatment of relapsed and refractory multiple myeloma | Semantic Scholar
ASCO 2016 Multiple Myeloma Update – Days One, Two, And Three
Treatment algorithm for newly diagnosed multiple myeloma and relapsed... | Download Scientific Diagram
Frontiers | Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis
Multiple myeloma current treatment algorithms | Blood Cancer Journal
Treatment schema for relapsed refractory multiple myeloma and commonly... | Download Scientific Diagram
Final results from a phase III randomized study comparing DVd with VA…
Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study - Yimer - 2019 - British Journal of Haematology - Wiley Online Library
3630-Multiple myeloma DVd (daratumumab bortezomib dexamethasone) overview | eviQ
Carfilzomib Twice Weekly in Combination with Dex and Daratumumab Vs Dara with Bortezomib and Dex
JPM | Free Full-Text | Targeted Therapies for Multiple Myeloma
Roundtable Discussion: Panelists Debate Therapy Options for R/R Multiple Myeloma With Renal Impairment
Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes - Landgren - 2017 - Journal of Internal Medicine - Wiley Online Library
Hemato | Free Full-Text | Why Immunotherapy Fails in Multiple Myeloma
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group - The Lancet Oncology
IberDd Versus DVd - Multiple Myeloma Clinical Trials
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016 in: Journal of the National Comprehensive Cancer Network Volume 14 Issue 4 (2016)
Daratumumab plus bortezomib or daratumumab plus lenalidomide as salvage therapy for patients with myeloma: initial follow-up of an Italian multicentre retrospective clinical experience by 'Rete Ematologica Pugliese' | SpringerLink
DPd against DVd for daratumumab-naïve patients with R/R multiple myeloma | VJHemOnc
Approved for use in:
